These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 11193378)

  • 1. [Angiotensin II receptor antagonists: candesartan cilexetil].
    Naka T; Kubo K; Nishikawa K; Inada Y; Furukawa Y
    Yakugaku Zasshi; 2000 Dec; 120(12):1261-75. PubMed ID: 11193378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new class of diacidic nonpeptide angiotensin II receptor antagonists: candesartan cilexetil.
    Naka T; Kubo K
    Curr Pharm Des; 1999 Jun; 5(6):453-72. PubMed ID: 10390609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new class of diacidic nonpeptide angiotensin II receptor antagonists: candesartan cilexetil.
    Naka T; Kubo K; Inada Y; Nishikawa K
    Drug Des Discov; 1999 Aug; 16(2):95-108. PubMed ID: 10533806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Candesartan cilexetil: pharmacological properties and protective effects against organ damage of a novel nonpeptide angiotensin II-receptor antagonist].
    Inada Y; Naka T
    Nihon Yakurigaku Zasshi; 2000 Mar; 115(3):151-60. PubMed ID: 10876800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Candesartan cilexetil: a review of its preclinical pharmacology.
    Nishikawa K; Naka T; Chatani F; Yoshimura Y
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S9-17. PubMed ID: 9330999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Newly emerging pharmacologic differences in angiotensin II receptor blockers.
    Oparil S
    Am J Hypertens; 2000 Jan; 13(1 Pt 2):18S-24S. PubMed ID: 10678284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Candesartan cilexetil: an angiotensin II receptor blocker.
    Stoukides CA; McVoy HJ; Kaul AF
    Ann Pharmacother; 1999 Dec; 33(12):1287-98. PubMed ID: 10630830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologic properties of candesartan cilexetil--possible mechanisms of long-acting antihypertensive action.
    Inada Y; Ojima M; Kanagawa R; Misumi Y; Nishikawa K; Naka T
    J Hum Hypertens; 1999 Jan; 13 Suppl 1():S75-80. PubMed ID: 10076925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Candesartan cilexetil: a new, long-acting, effective angiotensin II type 1 receptor blocker.
    Sever P
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S91-5. PubMed ID: 9331018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Angiotensin II receptor antagonist activities and mode of action of benzimidazole-7-carboxylic acid derivatives].
    Naka T
    Nihon Rinsho; 1993 Jun; 51(6):1575-9. PubMed ID: 8320837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Candesartan cilexetil: an angiotensin II-receptor blocker.
    See S; Stirling AL
    Am J Health Syst Pharm; 2000 Apr; 57(8):739-46. PubMed ID: 10786259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significance of angiotensin type 1 receptor blockade: why are angiotensin II receptor blockers different?
    Unger T
    Am J Cardiol; 1999 Nov; 84(10A):9S-15S. PubMed ID: 10588089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacological profiles of candesartan cilexetil (TCV-116)].
    Inada Y
    Nihon Rinsho; 1999 May; 57(5):1130-6. PubMed ID: 10361446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin II type 1 (AT1) receptor blockade in hypertensive women: benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide.
    Malmqvist K; Kahan T; Dahl M
    Am J Hypertens; 2000 May; 13(5 Pt 1):504-11. PubMed ID: 10826401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo inhibition of angiotensin receptors in the rat kidney by candesartan cilexetil: a comparison with losartan.
    Fabiani ME; Dinh DT; Nassis L; Casley DJ; Johnston CI
    Am J Hypertens; 2000 Sep; 13(9):1005-13. PubMed ID: 10981551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers.
    Hübner R; Högemann AM; Sunzel M; Riddell JG
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S19-25. PubMed ID: 9331000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemodynamic and hormonal effects of the angiotensin II antagonist, candesartan cilexetil, in patients with congestive heart failure.
    Yoshimura M; Yasue H
    Cardiology; 2000; 93(3):175-82. PubMed ID: 10965089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving antihypertensive efficacy while maintaining placebo-like tolerability.
    Sever PS
    Blood Press Suppl; 2000; 1():19-22. PubMed ID: 11059631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Symptom, Tolerability, Response to Exercise Trial of Candesartan Cilexetil in Heart Failure (STRETCH) Investigators.
    Riegger GA; Bouzo H; Petr P; Münz J; Spacek R; Pethig H; von Behren V; George M; Arens H
    Circulation; 1999 Nov; 100(22):2224-30. PubMed ID: 10577995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preserving target-organ function with candesartan cilexetil in patients with hypertension.
    Zannad F
    Blood Press Suppl; 2000; 1():36-9. PubMed ID: 11059635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.